Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
Vikas A Gupta, Ajay K Nooka, Sagar Lonial, Lawrence H BoiseDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USAAbstract: Treatment of refractory and/or relapsed multiple myeloma has been a challenging problem for over 20 years...
Saved in:
Main Authors: | Gupta VA, Nooka AK, Lonial S, Boise LH |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2013
|
Subjects: | |
Online Access: | https://doaj.org/article/d4e75dca93aa4addb989dbed6c00bdd2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS
by: Mehmut TURGUT, et al.
Published: (2021) -
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
by: Bhutani D, et al.
Published: (2017) -
Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
by: Illidge T, et al.
Published: (2012) -
TREATMENT OF RELAPSED, REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
by: Ebru Pekgüç, et al.
Published: (2021) -
Profile of elotuzumab and its potential in the treatment of multiple myeloma
by: Liu YC, et al.
Published: (2014)